See more : Computer And Technologies Holdings Limited (CXGEF) Income Statement Analysis – Financial Results
Complete financial analysis of Agilent Technologies, Inc. (A) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Agilent Technologies, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Yunnan Wenshan Electric Power Co.,Ltd. (600995.SS) Income Statement Analysis – Financial Results
- Upland Software, Inc. (UPLD) Income Statement Analysis – Financial Results
- Sotoh Co., Ltd. (3571.T) Income Statement Analysis – Financial Results
- Persistent Systems Limited (PERSISTENT.BO) Income Statement Analysis – Financial Results
- TZ Limited (TZL.AX) Income Statement Analysis – Financial Results
Agilent Technologies, Inc. (A)
About Agilent Technologies, Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51B | 6.83B | 6.85B | 6.32B | 5.34B | 5.16B | 4.91B | 4.47B | 4.20B | 4.04B | 6.98B | 6.78B | 6.86B | 6.62B | 5.44B | 4.48B | 5.77B | 5.42B | 4.97B | 5.14B | 7.18B | 6.06B | 6.01B | 8.40B | 10.77B | 8.33B | 7.95B |
| Cost of Revenue | 2.98B | 3.37B | 3.13B | 2.91B | 2.50B | 2.36B | 2.23B | 2.06B | 2.01B | 2.00B | 3.39B | 3.25B | 3.25B | 3.09B | 2.51B | 2.19B | 2.58B | 2.45B | 2.32B | 2.62B | 4.06B | 3.76B | 3.69B | 5.17B | 5.52B | 4.39B | 4.04B |
| Gross Profit | 3.54B | 3.47B | 3.72B | 3.41B | 2.84B | 2.81B | 2.69B | 2.41B | 2.20B | 2.04B | 3.59B | 3.54B | 3.60B | 3.53B | 2.93B | 2.29B | 3.20B | 2.97B | 2.66B | 2.52B | 3.12B | 2.29B | 2.32B | 3.23B | 5.25B | 3.94B | 3.92B |
| Gross Profit Ratio | 54.30% | 50.71% | 54.35% | 53.92% | 53.14% | 54.33% | 54.68% | 53.87% | 52.28% | 50.54% | 51.47% | 52.12% | 52.55% | 53.35% | 53.82% | 51.15% | 55.35% | 54.78% | 53.45% | 49.08% | 43.49% | 37.88% | 38.54% | 38.47% | 48.74% | 47.33% | 49.26% |
| Research & Development | 479.00M | 481.00M | 467.00M | 441.00M | 495.00M | 404.00M | 385.00M | 339.00M | 329.00M | 330.00M | 719.00M | 704.00M | 668.00M | 649.00M | 612.00M | 642.00M | 704.00M | 685.00M | 655.00M | 738.00M | 933.00M | 1.05B | 1.17B | 1.35B | 1.26B | 997.00M | 948.00M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.37B | 1.23B | 1.25B | 1.19B | 2.04B | 1.88B | 1.82B | 1.81B | 1.75B | 1.60B | 1.70B | 1.70B | 1.66B | 1.60B | 1.80B | 1.97B | 2.75B | 2.66B | 2.94B | 2.21B | 2.05B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.57B | 1.63B | 1.64B | 1.62B | 1.50B | 1.46B | 1.37B | 1.23B | 1.25B | 1.19B | 2.04B | 1.88B | 1.82B | 1.81B | 1.75B | 1.60B | 1.70B | 1.70B | 1.66B | 1.60B | 1.80B | 1.97B | 2.75B | 2.66B | 2.94B | 2.21B | 2.05B |
| Other Expenses | 0.00 | 0.00 | -39.00M | 92.00M | 66.00M | 16.00M | 55.00M | 19.00M | -10.00M | 17.00M | -81.00M | 8.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -121.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 477.00M |
| Operating Expenses | 2.05B | 2.12B | 2.10B | 2.06B | 1.99B | 1.86B | 1.76B | 1.57B | 1.58B | 1.52B | 2.76B | 2.58B | 2.49B | 2.46B | 2.36B | 2.25B | 2.40B | 2.39B | 2.19B | 2.34B | 2.74B | 3.02B | 3.92B | 4.01B | 4.20B | 3.20B | 3.48B |
| Cost & Expenses | 5.02B | 5.48B | 5.23B | 4.97B | 4.49B | 4.22B | 3.99B | 3.63B | 3.59B | 3.52B | 6.15B | 5.83B | 5.74B | 5.54B | 4.88B | 4.43B | 4.98B | 4.84B | 4.51B | 4.96B | 6.80B | 6.78B | 7.62B | 9.17B | 9.72B | 7.59B | 7.51B |
| Interest Income | 80.00M | 51.00M | 9.00M | 2.00M | 8.00M | 36.00M | 38.00M | 22.00M | 11.00M | 7.00M | 9.00M | 7.00M | 9.00M | 14.00M | 20.00M | 29.00M | 113.00M | 172.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -96.00M | 95.00M | 84.00M | 81.00M | 78.00M | 74.00M | 75.00M | 79.00M | 72.00M | 66.00M | 113.00M | 107.00M | 101.00M | 86.00M | 96.00M | 88.00M | 123.00M | 91.00M | 0.00 | 0.00 | 0.00 | 198.00M | 0.00 | 0.00 | 0.00 | 0.00 | 46.00M |
| Depreciation & Amortization | 0.00 | 271.00M | 317.00M | 321.00M | 308.00M | 238.00M | 210.00M | 214.00M | 247.00M | 253.00M | 383.00M | 372.00M | 301.00M | 253.00M | 202.00M | 162.00M | 201.00M | 191.00M | 170.00M | 186.00M | 292.00M | 362.00M | 735.00M | 734.00M | 495.00M | 475.00M | 477.00M |
| EBITDA | 1.49B | 1.70B | 1.99B | 1.73B | 1.35B | 1.28B | 1.18B | 1.10B | 863.00M | 778.00M | 648.00M | 758.00M | 1.45B | 1.40B | 788.00M | 257.00M | 1.14B | 775.00M | 634.00M | 396.00M | 275.00M | -358.00M | -872.00M | -345.00M | 1.38B | 862.00M | 919.00M |
| EBITDA Ratio | 22.86% | 24.92% | 27.82% | 27.88% | 23.00% | 23.84% | 25.05% | 24.46% | 20.51% | 19.79% | 16.36% | 19.73% | 20.84% | 20.23% | 14.47% | 5.31% | 16.73% | 14.21% | 9.17% | 5.72% | 8.69% | -6.57% | -15.51% | -4.11% | 13.34% | 14.04% | 11.56% |
| Operating Income | 1.49B | 1.35B | 1.62B | 1.35B | 846.00M | 941.00M | 928.00M | 841.00M | 615.00M | 522.00M | 831.00M | 951.00M | 1.12B | 1.07B | 566.00M | 47.00M | 795.00M | 584.00M | 464.00M | 181.00M | 386.00M | -725.00M | -1.61B | -778.00M | 1.05B | 741.00M | 442.00M |
| Operating Income Ratio | 22.86% | 19.76% | 23.63% | 21.32% | 15.85% | 18.23% | 18.88% | 18.81% | 14.64% | 12.93% | 11.90% | 14.02% | 16.32% | 16.19% | 10.40% | 1.05% | 13.77% | 10.77% | 9.33% | 3.52% | 5.38% | -11.97% | -26.74% | -9.27% | 9.77% | 8.89% | 5.56% |
| Total Other Income/Expenses | 33.00M | -11.00M | -114.00M | 13.00M | -4.00M | -22.00M | 42.00M | -38.00M | -71.00M | -42.00M | -190.00M | 473.00M | -76.00M | -39.00M | 126.00M | -40.00M | 20.00M | 86.00M | 163.00M | 85.00M | 117.00M | 30.00M | 60.00M | 301.00M | 111.00M | 46.00M | -46.00M |
| Income Before Tax | 1.52B | 1.34B | 1.50B | 1.36B | 842.00M | 919.00M | 946.00M | 803.00M | 544.00M | 480.00M | 646.00M | 859.00M | 1.04B | 1.03B | 692.00M | 7.00M | 815.00M | 670.00M | 627.00M | 254.00M | 440.00M | -690.00M | -1.55B | -477.00M | 1.16B | 787.00M | 396.00M |
| Income Before Tax Ratio | 23.36% | 19.60% | 21.96% | 21.52% | 15.77% | 17.80% | 19.25% | 17.96% | 12.95% | 11.89% | 9.25% | 12.67% | 15.21% | 15.60% | 12.71% | 0.16% | 14.11% | 12.36% | 12.61% | 4.94% | 6.13% | -11.39% | -25.74% | -5.68% | 10.80% | 9.45% | 4.98% |
| Income Tax Expense | 232.00M | 99.00M | 250.00M | 150.00M | 123.00M | -152.00M | 630.00M | 119.00M | 84.00M | 45.00M | 149.00M | 135.00M | -110.00M | 20.00M | 68.00M | 38.00M | 122.00M | 32.00M | 91.00M | 155.00M | 91.00M | 1.10B | -525.00M | -71.00M | 407.00M | 275.00M | 139.00M |
| Net Income | 1.29B | 1.24B | 1.25B | 1.21B | 719.00M | 1.07B | 316.00M | 684.00M | 460.00M | 398.00M | 497.00M | 724.00M | 1.15B | 1.01B | 624.00M | -31.00M | 693.00M | 638.00M | 3.31B | 327.00M | 349.00M | -2.06B | -1.03B | 168.00M | 757.00M | 512.00M | 257.00M |
| Net Income Ratio | 19.80% | 18.15% | 18.31% | 19.15% | 13.47% | 20.74% | 6.43% | 15.30% | 10.95% | 9.86% | 7.12% | 10.68% | 16.81% | 15.30% | 11.46% | -0.69% | 12.00% | 11.77% | 66.50% | 6.36% | 4.86% | -33.98% | -17.17% | 2.00% | 7.03% | 6.15% | 3.23% |
| EPS | 4.44 | 4.22 | 4.19 | 3.98 | 2.33 | 3.41 | 0.98 | 2.12 | 1.41 | 1.20 | 1.49 | 2.12 | 3.31 | 2.92 | 1.80 | -0.09 | 1.91 | 1.62 | 7.67 | 0.66 | 0.76 | -4.35 | -2.22 | 0.38 | 1.68 | 1.35 | 0.58 |
| EPS Diluted | 4.43 | 4.19 | 4.18 | 3.94 | 2.30 | 3.37 | 0.97 | 2.10 | 1.40 | 1.19 | 1.47 | 2.10 | 3.27 | 2.85 | 1.77 | -0.09 | 1.87 | 1.57 | 7.50 | 0.65 | 0.75 | -4.35 | -2.22 | 0.38 | 1.66 | 1.35 | 0.56 |
| Weighted Avg Shares Out | 290.00M | 294.00M | 299.00M | 304.00M | 309.00M | 314.00M | 321.00M | 322.00M | 326.00M | 333.00M | 333.00M | 341.00M | 348.00M | 347.00M | 347.00M | 346.00M | 363.00M | 394.00M | 431.00M | 494.00M | 483.00M | 473.00M | 465.00M | 458.00M | 449.00M | 380.00M | 443.10M |
| Weighted Avg Shares Out (Dil) | 291.00M | 296.00M | 300.00M | 307.00M | 312.00M | 318.00M | 325.00M | 326.00M | 329.00M | 335.00M | 338.00M | 345.00M | 353.00M | 355.00M | 353.00M | 346.00M | 371.00M | 406.00M | 441.00M | 500.00M | 490.00M | 473.00M | 465.00M | 458.00M | 455.00M | 457.50M | 458.93M |
Agilent to Announce Third-Quarter Fiscal Year 2024 Financial Results Aug. 21
History Says These Could Be 3 of the Best Healthcare Stocks to Own in the Second Half of 2024
Agilent Names Bret DiMarco Chief Legal Officer
Why Is Agilent (A) Down 0.5% Since Last Earnings Report?
Agilent's ESG Report Highlights Expansion of Solutions to Help Labs Manage Their Environmental Footprint
New Strong Sell Stocks for June 7th
Agilent (A) Boosts Reach to Lab Researchers With New Devices
Agilent Technologies, Inc. (A) Jefferies 2024 Global Healthcare Conference (Transcript)
Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
ePrep and Agilent Announce New Distribution Partnership for the ePrep(R) ONE Chromatography Sample Preparation Workstation
Source: https://incomestatements.info
Category: Stock Reports